PetVivo has been increasing in dollar volume, and obviously price since the second half of 2020. Shares have rose from a split adjusted low of approximately .50 to $17.00 per share and are accompanied with the making of a potential NASDAQ listing.
There are major benefits to up listing to a senior exchange. One benefit is the possibility that analysts are beginning to cover the stock. A covered stock refers to a public company’s shares for which one or more sell-side equity analysts publish research reports and investment recommendations for their clients.
Companies that trade on major exchanges have a far better chance of receiving coverage from independent research firms and investment banks, which will ultimately help drive market and investment activity in a particular stock. Most independent research firms and investment banks however do not provide coverage for companies trading on the OTC markets.
In case you missed it, PetVivo Holdings, Inc. (OTCQB: PETV) published a press release on December 29, 2020 announcing a reverse stock split in efforts to improve the company’s capital structure related to listing requirements for a planned future listing of the company’s common stock on the Nasdaq Capital Market.
In the early months after up listing, a company usually gets coverage from top analysts at different investment banks as well other independent research firms which will make the company’s stock more attractive to investors.
PetVivo Holdings, Inc. is moving in that direction.
PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Kush is expected to launch in Q1 2021, with sales in the $4.8 billion dog and horse therapeutics market, and Petvivo (OTCQB: PETV) currently has 16 products in its pipeline.
On November 23, 2020, PetVivo Holdings (OTCQB: PETV) filed an 8-K where the Company adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?” All of which are required by NASDAQ.
PetVivo Holdings’ Audit Committee will consist of three or more directors and each committee member will, among other requirements, qualify as an independent director, and at least one of them will qualify as an “audit committee financial expert”, all also as required by NASDAQ Rules.
PetVivo Holdings’ Compensation Committee will consist of two or more directors and each committee member will, among other requirements be independent in accordance with the NASDAQ Rules.
Nominating and Corporate Governance Committee:
PetVivo Holdings’ Nominating and Corporate Governance Committee will consist of two or more directors and each committee member will qualify as an independent director in accordance with the rules of the NASAQ Stock Market.
See page 11 of the “Nasdaq Official Listing Guide of June 2020”.
There is a niche biotech company called PetVivo, Holdings, Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets. PetVivo is benefiting from trials on the human side with a lower barrier to approval for pets.
More about the company:
The company recently announced a sponsored research agreement with Colorado State University (“CSU”) College of Veterinary Medicine and Biomedical Sciences to engage in a clinical study involving the treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH
PetVivo Holdings, Inc. (OTCQB: PETV) also recently announced that a company out of Orlando, Florida called nScrypt that designs and manufactures high-precision industrial Micro-dispensing and Direct Digital Manufacturing equipment, has just successfully 3D bio-printed PetVivo’s (OTCQB: PETV) biomaterial for orthopedic implants using its Bio-Fabrication Tool (BAT). To the best of the company’s knowledge, there is no other company that has the ability to provide these life-based components for the 3D printing marketplace.
The applications and cures for this technology are endless. Implants, replacements, up until and including the present, have been made with foreign ingredients like titanium and other metals. The future of this science now lies with the technology that allows for a more biologically familiar biomaterial. PetVivo’s biomaterial is made from the same components as the body’s natural tissue, allowing cells to be added to the structures being printed.
Ultimately, this breakthrough could lead to the creation of implants that actually mimic the bone itself.
Currently PetVivo Holdings, Inc. (OTCQB: PETV) has only 6 million shares outstanding and a market cap of $97 million according to OTCMarkets.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share (Pre-Split) by Marble Arch Research. You can download the full report here: – Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Goldman Research just announced a new report with its current target price under review. You can see the report here:
Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people.
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.